Laza Medical Raises $160 Million in Series B
GE HealthCare led the up-to-$160 million round to fund AI and robotic imaging for cardiac catheterization labs.
Updated on Nov. 4, 2026 in Heart Disease
Laza Medical, a Shifamed portfolio company, raised up to $160 million in Series B financing led by GE HealthCare. The round also drew Unorthodox Ventures, PA MedTech and AMED.
Why it matters
Cardiovascular procedures are growing more complex, and care teams need more consistent image guidance as demand for specialized imaging expertise rises. The financing targets that gap with AI-powered robotic imaging for cardiac interventions.
The figure is a company-announced Series B financing of up to $160 million, with no prior-round comparator disclosed. The system is not approved for sale anywhere, and no regulatory or commercial timeline was provided.
The players
GE HealthCare
GE HealthCare is a major medical imaging and healthcare technology company that led the Series B round and has expanded its collaboration with Laza Medical on intelligent cath lab imaging.
Shifamed
Shifamed is a medical device company founded by serial entrepreneur Amr Salahieh, and Laza Medical is one of its portfolio companies.
The details
Laza Medical combines AI and robotics to simplify procedural imaging in cardiac interventions, and the financing will support development of intelligent imaging for the cardiac catheterization lab. Dr. Firas Zahr used the software during a first-in-human clinical study at Oregon Health Sciences University Hospital last year, and company leadership says the solution will streamline processes and reduce variability.
Timeline
Last year: first-in-human clinical study of the software at Oregon Health Sciences University Hospital.
November 5, 2026: Laza Medical announced the $160 million Series B financing.
Roadmap
Robotic-assisted cardiac interventions are moving toward AI-guided imaging to manage rising procedural complexity. Laza Medical's Series B positions it to compete in that emerging segment of the cath lab market.
Patients undergoing cardiac procedures may eventually benefit from more consistent image guidance, though the system is not yet approved for commercial use. No changes to current treatment options or insurance coverage follow from this financing alone.
The takeaway
Imaging innovation in the cath lab is becoming a focus for both device makers and large imaging companies. Readers should watch for regulatory milestones before expecting any clinical availability.
Further reading
Explore more on Heart Disease to see how cardiac procedure technology is evolving.
